CN102973569B - Pharmaceutical composition with cefminox sodium sterile mixed powder form - Google Patents
Pharmaceutical composition with cefminox sodium sterile mixed powder form Download PDFInfo
- Publication number
- CN102973569B CN102973569B CN201210545737.2A CN201210545737A CN102973569B CN 102973569 B CN102973569 B CN 102973569B CN 201210545737 A CN201210545737 A CN 201210545737A CN 102973569 B CN102973569 B CN 102973569B
- Authority
- CN
- China
- Prior art keywords
- sodium
- cefminox
- pharmaceutical composition
- sodium benzoate
- natrium carbonicum
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
The invention relates to a pharmaceutical composition with a cefminox sodium sterile mixed powder form, and the pharmaceutical composition comprises cefminox sodium, anhydrous sodium carbonate and sodium benzoate, wherein the mass ratio of the cefminox sodium, the anhydrous sodium carbonate and the sodium benzoate is 100g:(0.1-0.5)g:(0.1-1.0)g. Due to the combined application of the cefminox sodium, the anhydrous sodium carbonate and the sodium benzoate, the heat stability of the cefminox sodium can be greatly improved, and the stability of the cefminox sodium in a solution state can be improved, so that the clinical use safety is improved. Furthermore, the invention also relates to a preparation method of the pharmaceutical composition, and the preparation method is simple and practicable in technology, thus being suitable for large-scale production.
Description
Technical field
The invention belongs to field of medicaments, relate in particular to the pharmaceutical composition of a kind of Cefminox sodium without bacterium mix powder form, containing natrium carbonicum calcinatum, sodium benzoate in this compositions.
Background technology
Cefminox sodium, English Cefminox Sodium by name, chemistry (6R by name, 7S)-7 β-[(S)-2-[(2-amino-2-carboxyethyl) sulfur] acetylamino]-7 α-methoxyl group-3-[[(1-methyl isophthalic acid H-tetrazolium-5-base) sulfur] methyl]-8-oxo-5-thia-1-azabicyclo [4.2.0] oct-2-ene-2-carboxylic acid sodium salt heptahydrate, for applying cephalosporin more widely clinically, its structural formula is:
Molecular formula: C
16h
20n
7naO
7s
3.7H
2o, molecular weight: 667.66.
Cefminox sodium is the Third generation Cephalosporins antibiotic developed by Japanese Meiji company, there is broad spectrum antibiotic activity to gram positive bacteria and gram negative bacteria, have very strong antibacterial action to escherichia coli, Klebsiella, hemophilus influenza, Proteus and bacteroides fragilis especially.Be applicable to respiratory system infection and urinary system infection, abdominal cavity infection and the pelvic infections such as bronchitis, tonsillitis, pneumonia.Its mechanism of action is that the penicillin-binding protein (pBP) to the usual application point of beta-lactam antibiotic shows very strong affinity, wall synthesis capable of inhibiting cell, and be combined with Peptidoglycan, resist Peptidoglycan and be combined to promote bacteriolyze with lipoprotein, show very strong sterilizing power at short notice.
Cefminox sodium listing is the sterile powder injection for intravenous drip.Because Cefminox sodium is unstable, extremely unstable especially in aqueous, clinically very easily degrades with during bulk capacity injection compatibility, thus causes active constituents of medicine content to reduce, and color and luster is strengthened, the rising of polymeric impurities content.In addition, the Cefminox sodium resting period is long, also usually makes active constituents of medicine content reduce, darkens, and polymer content raises.
Application number be 201110258681.8 Chinese patent application disclose a kind of Cefminox sodium crystalline compounds and composition powder pin thereof.Described Cefminox sodium crystalline compounds powder X-ray diffraction algoscopy measures, and the X-ray powder diffraction pattern represented with the 2 θ ± 0.2 ° angle of diffraction demonstrates characteristic diffraction peak at 5.1 °, 6.9 °, 8.5 °, 10.3 °, 12.1 °, 15.1 °, 15.9 °, 17.4 °, 19.5 °, 21.7 ° and 24. ° of 6 place.Described composition powder injection component is described Cefminox sodium crystalline compounds 95 ~ 100 parts, sodium benzoate 0.1 ~ 1 part.
CN101780087A provides a kind of anti-infective medicament composition containing Cefminox sodium.Said composition is by Cefminox sodium, Na
2hPO
4/ NaH
2pO
4with arginine composition, wherein, Cefminox sodium: Na
2hPO
4/ NaH
2pO
4: arginine is 100:0.1 ~ 5:1 ~ 5.By Cefminox sodium, Na
2hPO
4/ NaH
2pO
4solve Cefminox sodium facile hydrolysis in prior art with arginic combination, preserve and problem unstable after clinical pharmacy, pharmaceutical composition stable in properties of the present invention, storage conveniently, enhance clinical drug safety.
Said method to some extent solves the problem of product stability, but because Cefminox sodium is being deposited in process, often there is degraded and polyreaction, along with the prolongation of resting period in production, storage and use procedure, its high polymer content increases, and the risk making human body produce anaphylactic reaction increases.
The present inventor has obtained a kind of compositions being different from prior art through lot of experiments, namely combines with Cefminox sodium and natrium carbonicum calcinatum, sodium benzoate.By test, surprisingly find that said composition has excellent heat stability, technique is simple, and repeatability is strong, is suitable for suitability for industrialized production, thus completes the present invention.
Summary of the invention
The object of the present invention is to provide a kind of Cefminox sodium without the pharmaceutical composition of bacterium mix powder form, said composition is by the Combination application of Cefminox sodium and natrium carbonicum calcinatum, sodium benzoate, the heat stability of Cefminox sodium is improved greatly, also improve the stability of Cefminox sodium under solution state simultaneously, thus improve the safety of Clinical practice.
For realizing object of the present invention, the present invention adopts following technical scheme:
A kind of Cefminox sodium is without the pharmaceutical composition of bacterium mix powder form, wherein, described pharmaceutical composition is made up of Cefminox sodium, natrium carbonicum calcinatum and sodium benzoate, and in described pharmaceutical composition, the mass ratio of Cefminox sodium and natrium carbonicum calcinatum and sodium benzoate is 100g:0.1 ~ 0.5g:0.1 ~ 1.0g.
In described pharmaceutical composition, Cefminox sodium is 100g:0.3g:0.4g with the preferred mass ratio of natrium carbonicum calcinatum and sodium benzoate.
Described pharmaceutical composition is that Cefminox sodium makes sterilized powder with natrium carbonicum calcinatum, sodium benzoate after mixing by described mass ratio after aseptic subpackaged, is sub-packed in cillin bottle.Sterilized powder can carry out subpackage by the specification of 0.5g/ bottle, 1.0g/ bottle, 2.0g/ bottle etc.Here specification is in Cefminox sodium active ingredient.Gained pharmaceutical composition is 5.0 ~ 7.0 by solution ph after dissolution with solvents.
Meanwhile, the present invention also aims to provide the preparation method of described pharmaceutical composition, described preparation method technique simple possible, be applicable to industrialized great production.
Specifically, described preparation method makes aseptic powder injection after being mixed by described mass ratio with natrium carbonicum calcinatum and sodium benzoate by Cefminox sodium after aseptic subpackaged.
Through aseptic subpackaged after make sterilized powder with natrium carbonicum calcinatum, sodium benzoate after mixing by described mass ratio by Cefminox sodium, be sub-packed in cillin bottle.Sterilized powder can carry out subpackage by the specification of 0.5g/ bottle, 1.0g/ bottle, 2.0g/ bottle etc.Here specification is in Cefminox sodium active ingredient.Gained Cefminox sodium, without the pharmaceutical composition of bacterium mix powder form, is 5.0 ~ 7.0 by solution ph after dissolution with solvents.
As a preferred embodiment of the present invention, described natrium carbonicum calcinatum and/or sodium benzoate are through pretreated.
Be specially, described natrium carbonicum calcinatum be adopt carry out with the following method pretreated:
Sodium carbonate crude product is added to the water, is stirred to dissolve, add activated carbon decolorizing, filter, obtain sodium carbonate liquor, under the condition stirred, in sodium carbonate liquor, adding methanol, separating out to there being crystal; Leave standstill, filter, by methanol wash, dry, pulverize and sieve, obtain pretreated natrium carbonicum calcinatum.
In above-mentioned preprocess method, described sodium carbonate and the volume ratio of methanol solution are 1 ~ 2:5.
Described leaves standstill as leaving standstill 4 ~ 8 hours, preferably 6 hours; Described sieves as crossing 80 ~ 120 mesh sieves, preferably 100 mesh sieves.
In the present invention, described sodium benzoate adopt carry out with the following method pretreated:
Sodium benzoate crude product is added to the water, is stirred to dissolve, add activated carbon decolorizing, filter, obtain PhCOONa solution, under the condition stirred, in PhCOONa solution, adding ethanol, separating out to there being crystal; Leave standstill, filter, by washing with alcohol, dry, pulverize and sieve, obtain sodium benzoate.
In above-mentioned preprocess method, described sodium benzoate and the volume ratio of alcoholic solution are 1:2 ~ 5.
Described leaves standstill as leaving standstill 10 ~ 12 hours; Described sieves as crossing 80 ~ 120 mesh sieves, preferably 100 mesh sieves.
As one of the present invention most preferably scheme, Cefminox sodium of the present invention comprises the steps: without the preparation method of the pharmaceutical composition of bacterium mix powder form
1) pretreatment of natrium carbonicum calcinatum: sodium carbonate crude product is added to the water, is stirred to dissolve, add activated carbon decolorizing, filter, obtain sodium carbonate liquor, under the condition stirred, in sodium carbonate liquor, the ratio of 1 ~ 2:5 adds methanol by volume, has crystal to separate out; Leave standstill 6h, filter, by methanol wash, dry, pulverize 100 mesh sieves, and obtained natrium carbonicum calcinatum;
2) sodium benzoate pretreatment: sodium benzoate crude product is added to the water, is stirred to dissolve, add activated carbon decolorizing, filter, obtain PhCOONa solution, under the condition stirred, in PhCOONa solution, the ratio of 1:2 ~ 5 adds ethanol by volume, has crystal to separate out; Leave standstill 10h ~ 12h, filter, by washing with alcohol, dry, pulverize 100 mesh sieves, and obtained sodium benzoate;
3) Cefminox sodium and natrium carbonicum calcinatum obtained above, sodium benzoate are placed in sterile chamber, use three-dimensional mixer to carry out mix homogeneously, carry out aseptic subpackaged after mixing.
Wherein, the mass ratio of Cefminox sodium and natrium carbonicum calcinatum, sodium benzoate is 100g:0.1 ~ 0.5g:0.1 ~ 1.0g, preferred 100g:0.3g:0.4g.
Described pharmaceutical composition is that Cefminox sodium makes sterilized powder with natrium carbonicum calcinatum, sodium benzoate after mixing by described mass ratio after aseptic subpackaged, is sub-packed in cillin bottle.Sterilized powder can carry out subpackage by the specification of 0.5g/ bottle, 1.0g/ bottle, 2.0g/ bottle etc.Here specification is in Cefminox sodium active ingredient.Gained pharmaceutical composition is 5.0 ~ 7.0 by solution ph after dissolution with solvents.
Compared with prior art, tool of the present invention has the following advantages:
(1) in cefminox composition of sodium provided by the present invention, natrium carbonicum calcinatum is pH value regulator, can accelerate Cefminox sodium dissolution velocity in a solvent.
(2) in cefminox composition of sodium provided by the present invention, sodium benzoate is stabilizing agent, can improve Cefminox sodium stability in storage process and in a solvent.
(3) the preparation method technique of cefminox composition of sodium provided by the present invention is simple, and repeatability is strong, is suitable for suitability for industrialized production.
(4) cefminox composition of sodium provided by the present invention has good heat stability, and substantially increases the stability under solution state, improves drug safety and effectiveness, reduces the incidence rate of untoward reaction.
Detailed description of the invention
Be below the specific embodiment of the present invention, described embodiment is to further describe the present invention, instead of restriction the present invention.
[embodiment 1] Cefminox sodium aseptic powder injection
Specification:
Preparation method:
1, interior packaging material process
The technique cleaning routinely of antibiotic glass bottle, plug, aluminium lid, oven dry, sterilizing, for subsequent use;
2, concrete steps
(1) natrium carbonicum calcinatum and natrium carbonicum calcinatum, the sodium benzoate of recipe quantity is taken, mix homogeneously in sterile chamber;
(2) product inspection in the middle of;
(3) undertaken aseptic subpackaged by specification;
(4) tamponade, lid is rolled;
(5) packaging, Quan Jian, warehouse-in.
[embodiment 2] Cefminox sodium aseptic powder injection
Specification:
Preparation method: with example of formulations 1.
[embodiment 3] Cefminox sodium aseptic powder injection
Specification:
Preparation method: with embodiment 1.
[embodiment 4] Cefminox sodium aseptic powder injection
Specification:
Preparation method: with example of formulations 1.
[embodiment 5] Cefminox sodium aseptic powder injection
Specification:
Preparation method: with example of formulations 1.
[embodiment 6] Cefminox sodium aseptic powder injection
Specification:
Preparation method: with example of formulations 1.
[embodiment 7] Cefminox sodium aseptic powder injection
Specification:
Preparation method:
1) pretreatment of natrium carbonicum calcinatum: sodium carbonate crude product is added to the water, is stirred to dissolve, add activated carbon decolorizing, filter, obtain sodium carbonate liquor, under the condition stirred, in sodium carbonate liquor, the ratio of 1.5:5 adds methanol by volume, has crystal to separate out; Leave standstill 6h, filter, by methanol wash, dry, pulverize 100 mesh sieves, and obtained natrium carbonicum calcinatum;
2) pretreatment of sodium benzoate: sodium benzoate crude product is added to the water, is stirred to dissolve, add activated carbon decolorizing, filter, obtain PhCOONa solution, under the condition stirred, in PhCOONa solution, the ratio of 1:3 adds ethanol by volume, has crystal to separate out; Leave standstill 11h, filter, by washing with alcohol, dry, pulverize 100 mesh sieves, and obtained sodium benzoate;
3) Cefminox sodium and natrium carbonicum calcinatum obtained above, sodium benzoate are placed in sterile chamber, use three-dimensional mixer to carry out mix homogeneously, carry out aseptic subpackaged after mixing.
[embodiment 8] Cefminox sodium aseptic powder injection
Specification:
Preparation method:
1) pretreatment of natrium carbonicum calcinatum: be added to the water by sodium carbonate crude product, be stirred to dissolve, add activated carbon decolorizing, filters, obtains sodium carbonate liquor, and under the condition stirred, in sodium carbonate liquor, the ratio of 1:5 adds methanol by volume, has crystal to separate out; Leave standstill 4h, filter, by methanol wash, dry, pulverize 80 mesh sieves, and obtained natrium carbonicum calcinatum;
2) sodium benzoate pretreatment: sodium benzoate crude product is added to the water, is stirred to dissolve, add activated carbon decolorizing, filter, obtain PhCOONa solution, under the condition stirred, in PhCOONa solution, the ratio of 1:2 adds ethanol by volume, has crystal to separate out; Leave standstill 10h, filter, by washing with alcohol, dry, pulverize 80 mesh sieves, and obtained sodium benzoate;
3) with embodiment 7.
[embodiment 9] Cefminox sodium aseptic powder injection
Specification:
Preparation method:
1) pretreatment of natrium carbonicum calcinatum: be added to the water by sodium carbonate crude product, be stirred to dissolve, add activated carbon decolorizing, filters, obtains sodium carbonate liquor, and under the condition stirred, in sodium carbonate liquor, the ratio of 2:5 adds methanol by volume, has crystal to separate out; Leave standstill 8h, filter, by methanol wash, dry, pulverize 120 mesh sieves, and obtained natrium carbonicum calcinatum;
2) sodium benzoate pretreatment: sodium benzoate crude product is added to the water, is stirred to dissolve, add activated carbon decolorizing, filter, obtain PhCOONa solution, under the condition stirred, in PhCOONa solution, the ratio of 1:5 adds ethanol by volume, has crystal to separate out; Leave standstill 12h, filter, by washing with alcohol, dry, pulverize 120 mesh sieves, and obtained sodium benzoate;
3) with embodiment 7.
Comparative example 1
Heat stabilization test
Cefminox sodium is being deposited in process, and particularly under the condition of high temperature (> 40 DEG C), often degraded and polyreaction occur, thus cause active constituents of medicine content to reduce, color and luster is strengthened, and polymeric impurities content raises.This comparative example is for investigating the thermal stability difference of cefminox composition of sodium prepared by the present invention and Cefminox sodium of the prior art.
In this comparative example, each sample is numbered:
Trial target 1: the cefminox composition of sodium prepared by the embodiment of the present invention 3;
Trial target 2: the cefminox composition of sodium prepared by the embodiment of the present invention 5;
Reference substance 1: according to the cefminox composition of sodium that the method for the embodiment 8 of application number 201110258681.8 is obtained;
The prescription 1 of reference substance 2:CN101780087A and the cefminox sodium composition sterile powder pin obtained by preparation method.
Each sample is exposed to respectively relative humidity is 75%, temperature is under the environment of 60 DEG C, after adopting high performance liquid chromatography test different time, the content of Cefminox sodium and molecular exclusion chromatography measure the content of high molecular polymer (high performance liquid chromatography and molecular exclusion chromatography are according to pharmacopeia in 2005 second, the related conditions of annex VD and annex VH carries out measuring), the results are shown in Table 1.
Table 1, heat stability comparative result
As can be seen from the above table, the heat stability of the cefminox composition of sodium prepared by method of the present invention is adopted significantly to be better than the cefminox composition of sodium adopting the method for prior art to obtain.
Also carried out above-mentioned test to the cefminox composition of sodium prepared by other embodiment of the present invention, its result obtained is similar.
Comparative example 2
High wet test
This comparative example is for investigating the hygroscopicity difference of the cefminox composition of sodium prepared by the present invention and the cefminox composition of sodium prepared by employing art methods.
Cefminox composition of sodium representated by sample number into spectrum comparatively example 1 on year-on-year basis.
Each sample opening is put in clean culture dish, spread out into≤thin layer that 5mm is thick, each two parts, put into constant humidity hermetic container respectively, 10 days are placed, in the 5th day and sampling in the 10th day, by the moisture of loss on drying experiment measuring each sample under 25 DEG C of conditions respectively at relative humidity 75% and 92.5%, result of the test compared with 0 day, and result of the test is in table 2.
Table 2, high humidity result of the test
As can be seen from the above table, the cefminox composition of sodium prepared by the present invention is substantially non-hygroscopic under high humidity conditions, and its stability under high humidity environment is consistent with the cefminox composition of sodium prepared by art methods.
Also carried out above-mentioned test to the cefminox composition of sodium prepared by other embodiment of the present invention, its result obtained is similar.
Comparative example 3
Solution stability testing
This comparative example is for investigating cefminox composition of sodium prepared by the present invention with the Cefminox sodium composition dissolves adopted prepared by art methods in water, comparison solution stability.
Cefminox composition of sodium representated by sample number into spectrum comparatively example 1 on year-on-year basis.
The 10ml that each sample added water respectively dissolves, and places 8 hours under room temperature 25 DEG C of conditions, and every sampling in 2 hours, content, the related substance of Cefminox sodium after employing high performance liquid chromatography test different time, result of the test was in table 3.
Table 3, solution stability testing result
As can be seen from the above table, the cefminox composition of sodium prepared by the present invention is more stable in water, related substance and changes of contents not obvious, aqueous stability under the same conditions is significantly better than adopting and Cefminox sodium prepared by art methods.
Also carried out above-mentioned test to the cefminox composition of sodium prepared by other embodiment of the present invention, its result obtained is similar.
Test example 1
Influence factor tests
By the cefminox sodium for injection prepared by the embodiment of the present invention 3 under the condition of simulation listing packaging, place 10 days under high temperature (60 DEG C), under hot conditions, related substance increases to some extent, and outside slightly changing under illumination condition, other indices are without significant change.Result of the test is in table 4.
Table 4, influence factor's result of the test
Test example 2
Accelerated test
By the cefminox sodium for injection simulation listing packaging prepared by the embodiment of the present invention 3, place 6 months under temperature 40 DEG C, relative humidity 75% condition, respectively at the 1st, 2,3, sampling in June, investigate character, acidity, clarity and the project such as color, visible foreign matters, and with 0 day results contrast.Result of the test is in table 5.
Table 5, cefminox sodium for injection accelerated test result
Identical test is carried out to the cefminox sodium for injection of other embodiment of the present invention, there is similar result.
Test example 3
Long term test
By the cefminox sodium for injection simulation listing packaging prepared by the embodiment of the present invention 3, at room temperature, respectively at the 3rd, sampling in 6,9,12 months, investigate character, acidity, clarity and the project such as color, visible foreign matters, and with 0 day results contrast.Result of the test is shown in Table 6:
Table 6, cefminox sodium for injection long-term test results
Identical test is carried out to the cefminox sodium for injection of other embodiment of the present invention, there is similar result.
Claims (8)
1. a Cefminox sodium is without the pharmaceutical composition of bacterium mix powder form, it is characterized in that, described pharmaceutical composition is made up of Cefminox sodium, natrium carbonicum calcinatum and sodium benzoate, and in described pharmaceutical composition, the mass ratio of Cefminox sodium and natrium carbonicum calcinatum and sodium benzoate is 100g:0.3g:0.4g; The preparation method of described pharmaceutical composition makes aseptic powder injection after being mixed by described mass ratio with natrium carbonicum calcinatum and sodium benzoate by Cefminox sodium after aseptic subpackaged, and described natrium carbonicum calcinatum and/or sodium benzoate are through pretreated;
Wherein, described natrium carbonicum calcinatum be adopt carry out with the following method pretreated:
Sodium carbonate crude product is added to the water, is stirred to dissolve, add activated carbon decolorizing, filter, obtain sodium carbonate liquor, under the condition stirred, in sodium carbonate liquor, adding methanol, separating out to there being crystal; Leave standstill, filter, by methanol wash, dry, pulverize and sieve, obtain pretreated natrium carbonicum calcinatum;
Described sodium benzoate adopt carry out with the following method pretreated:
Sodium benzoate crude product is added to the water, is stirred to dissolve, add activated carbon decolorizing, filter, obtain PhCOONa solution, under the condition stirred, in PhCOONa solution, adding ethanol, separating out to there being crystal; Leave standstill, filter, by washing with alcohol, dry, pulverize and sieve, obtain sodium benzoate.
2. the preparation method of a pharmaceutical composition according to claim 1, it is characterized in that, described preparation method makes aseptic powder injection after being mixed by described mass ratio with natrium carbonicum calcinatum and sodium benzoate by Cefminox sodium after aseptic subpackaged, and described natrium carbonicum calcinatum and/or sodium benzoate are through pretreated;
Wherein, described natrium carbonicum calcinatum be adopt carry out with the following method pretreated:
Sodium carbonate crude product is added to the water, is stirred to dissolve, add activated carbon decolorizing, filter, obtain sodium carbonate liquor, under the condition stirred, in sodium carbonate liquor, adding methanol, separating out to there being crystal; Leave standstill, filter, by methanol wash, dry, pulverize and sieve, obtain pretreated natrium carbonicum calcinatum;
Described sodium benzoate adopt carry out with the following method pretreated:
Sodium benzoate crude product is added to the water, is stirred to dissolve, add activated carbon decolorizing, filter, obtain PhCOONa solution, under the condition stirred, in PhCOONa solution, adding ethanol, separating out to there being crystal; Leave standstill, filter, by washing with alcohol, dry, pulverize and sieve, obtain sodium benzoate.
3. the preparation method of pharmaceutical composition according to claim 2, is characterized in that, described sodium carbonate liquor and the volume ratio of methanol are 1 ~ 2:5.
4. the preparation method of pharmaceutical composition according to claim 2, is characterized in that, in the pretreatment of described natrium carbonicum calcinatum, described leaves standstill as leaving standstill 4 ~ 8 hours; Described sieves as crossing 80 ~ 120 mesh sieves.
5. the preparation method of pharmaceutical composition according to claim 4, is characterized in that, described leaves standstill as leaving standstill 6 hours; Described sieves as crossing 100 mesh sieves.
6. the preparation method of pharmaceutical composition according to claim 2, is characterized in that, described sodium benzoate and the volume ratio of alcoholic solution are 1:2 ~ 5.
7. the preparation method of pharmaceutical composition according to claim 2, is characterized in that, in the pretreatment of described sodium benzoate, described leaves standstill as leaving standstill 10 ~ 12 hours; Described sieves as crossing 80 ~ 120 mesh sieves.
8. the preparation method of pharmaceutical composition according to claim 7, is characterized in that, described sieves as crossing 100 mesh sieves.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201210545737.2A CN102973569B (en) | 2012-12-14 | 2012-12-14 | Pharmaceutical composition with cefminox sodium sterile mixed powder form |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201210545737.2A CN102973569B (en) | 2012-12-14 | 2012-12-14 | Pharmaceutical composition with cefminox sodium sterile mixed powder form |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN102973569A CN102973569A (en) | 2013-03-20 |
| CN102973569B true CN102973569B (en) | 2015-02-11 |
Family
ID=47848104
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201210545737.2A Active CN102973569B (en) | 2012-12-14 | 2012-12-14 | Pharmaceutical composition with cefminox sodium sterile mixed powder form |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102973569B (en) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104129803A (en) * | 2014-08-12 | 2014-11-05 | 天津市嵩锐医药科技有限公司 | Stable sodium nitroprusside crystal compound, pharmaceutical composition and preparation method thereof |
| CN106562932A (en) * | 2016-09-30 | 2017-04-19 | 华北制药河北华民药业有限责任公司 | Preparation method of cefminox sodium powder-needle preparation for injection |
| CN110025584A (en) * | 2019-05-06 | 2019-07-19 | 哈尔滨誉衡制药有限公司 | A kind of preparation method of cefminox sodium ejection preparation |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1706387A (en) * | 2004-06-09 | 2005-12-14 | 北京盛世伟唐科技有限公司 | Stable cephalosporin powder injection |
| CN101036657A (en) * | 2006-03-15 | 2007-09-19 | 广州白云山天心制药股份有限公司 | Stable cefoperazone medicine prparation |
| CN101584665A (en) * | 2009-07-17 | 2009-11-25 | 山东罗欣药业股份有限公司 | Cefotiam hydrochloride medicament composition sterile powder injection and preparation method thereof |
| CN102276630A (en) * | 2011-09-02 | 2011-12-14 | 山东罗欣药业股份有限公司 | Cefminox sodium crystalline compound and composition powder injection thereof |
-
2012
- 2012-12-14 CN CN201210545737.2A patent/CN102973569B/en active Active
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1706387A (en) * | 2004-06-09 | 2005-12-14 | 北京盛世伟唐科技有限公司 | Stable cephalosporin powder injection |
| CN101036657A (en) * | 2006-03-15 | 2007-09-19 | 广州白云山天心制药股份有限公司 | Stable cefoperazone medicine prparation |
| CN101584665A (en) * | 2009-07-17 | 2009-11-25 | 山东罗欣药业股份有限公司 | Cefotiam hydrochloride medicament composition sterile powder injection and preparation method thereof |
| CN102276630A (en) * | 2011-09-02 | 2011-12-14 | 山东罗欣药业股份有限公司 | Cefminox sodium crystalline compound and composition powder injection thereof |
Non-Patent Citations (1)
| Title |
|---|
| 经典恒温加速法和多元线性模型预测头孢米诺钠水溶液的稳定性;汝玲等;《中国药房》;20060915;第17卷(第19期);参见第1502页左栏第2段 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN102973569A (en) | 2013-03-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102659818B (en) | Hydrochloric acid cefotiam crystalline compound, preparation method thereof and medicine combination containing compound | |
| CN102924483B (en) | Ceftazidime crystal compound, preparation method of compound and pharmaceutical composition of compound in sterile mixed powder form | |
| CN102838623B (en) | Cefminox sodium compound crystal, preparation method of cefminox sodium compound crystal and sterile powder injection containing cefminox sodium compound crystal | |
| CN102973569B (en) | Pharmaceutical composition with cefminox sodium sterile mixed powder form | |
| CN102875576A (en) | Synthesis of antibiotic ceftazidime, ceftazidime for injection and preparation method of ceftazidime | |
| CN104873466A (en) | Ceftriaxone sodium powder-injection for injection | |
| CN103232449B (en) | Aztreonam compound, as well as preparation method and pharmaceutical composition thereof | |
| CN103524532B (en) | Ceftizoxime sodium compound crystal form, and preparing method and pharmaceutical preparation thereof | |
| CN102526040B (en) | Method for preparing composition of mezlocillin sodium and sulbactam sodium for injection in ratio of 4: 1 | |
| CN103601739A (en) | Cefoxitin sodium compound and preparation method thereof | |
| CN103145736B (en) | Medicine composition containing cefamandole nafate compound | |
| CN102247375B (en) | Cefotetan disodium for injection, and preparation method thereof | |
| CN103073562A (en) | Method for refining cefamandole nafate, cefamandole nafate and application thereof | |
| CN102286002B (en) | Cefpiramide sodium powder injection composition and preparation method thereof | |
| CN104622695A (en) | Cefoxitin sodium powder preparation for injection | |
| CN102936254B (en) | Drug composition containing ceftizoxime sodium compound | |
| AU2012389714B2 (en) | Cocrystal of piperacillin sodium and sulbactam sodium and preparation method thereof, as well as pharmaceutical compositions containing same and uses thereof | |
| CN101829119B (en) | Cefodizime sodium composition and powder injection | |
| CN103191061B (en) | Cefbuperazone sodium composition powder for injection and preparation method thereof | |
| CN103191062A (en) | Sulbenicillin sodium injection | |
| CN103304604B (en) | Clindamycin phosphate compound and preparation method and pharmaceutical composition thereof | |
| CN105055420A (en) | Medicine cefamandole nafate composition for treating bacterial infection | |
| CN105622635A (en) | Ceftizoxime sodium novel crystal form capable of reducing anaphylactic reactions and preparation thereof | |
| CN104961751A (en) | Ceftezole sodium compound and medicinal preparation including same | |
| CN104844624A (en) | Cefoperazone sodium-sulbactam sodium eutectic crystal and composition, and preparation methods thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant |